Results 131 to 140 of about 77,580 (287)

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date. [PDF]

, 2018
Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults in the United States. Advances over the past 20 years in understanding the immune-mediated pathophysiology of psoriasis have led to the development of targeted biologic
Beck, Kristen M, Liao, Wilson, Sanchez, Isabelle M, Yang, Eric J   +3 more
core  

The Effect of Social Media Intervention as a Reminder and Educational Tool to Increase Treatment Adherence in Patients With Psoriasis: A Randomized Controlled Trial

JEADV Clinical Practice, EarlyView.
In a 12‐week randomized trial of 159 psoriasis patients, educational messages and treatment reminders delivered through Facebook improved treatment adherence, reduced disease severity, and enhanced quality of life. Three times‐weekly messages provided the greatest benefits, including superior adherence, clearer skin, and higher patient satisfaction ...
Jennifer Lavina T. Ngo, Lily Lyralin L. Tumalad   +1 more
wiley   +1 more source

Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. [PDF]

Clin Rheumatol, 2023
Weinstein CLJ, Meehan AG, Lin J, Briscoe SD, Govoni M.   +4 more
europepmc   +1 more source

Useful Instruments for Psoriasis Patients’ Follow‐Up in Teleconsultation Setting

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Teledermatology may be beneficial for psoriasis management and a working group of the International Psoriasis Council recently outlined the value of patient questionnaires in teledermatology. Objectives Identify instruments that could optimise psoriasis evaluation when completed before a teleconsultation; assess patients’ and ...
Emmanuel Mahé, Nicole Jouan, Delphine Devulder, Pascale Zukervar, Dorian Petonnet, Gaelle Desamericq, Theo Cerceau, Stéphane Bouée, Anne Bouloc   +8 more
wiley   +1 more source

Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis

Biologics: Targets & Therapy, 2014
Dario Kivelevitch, Bobbak Mansouri, Alan Menter Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA Abstract: Psoriasis is a chronic, immune-mediated inflammatory disease affecting both the skin and joints.
Kivelevitch D, Mansouri B, Menter A
doaj  

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. [PDF]

RMD Open, 2023
Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H, Shaw T, Mease PJ, Guttman-Yassky E.   +13 more
europepmc   +1 more source

Clinical Features and Therapeutic Outcomes in Pyoderma Gangrenosum: A Prospective Cohort Study

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis highly associated with systemic comorbidities. Accurate diagnosis and treatment remain challenging due to its rarity and clinical mimickers. Objectives To evaluate demographic, clinical features and treatment outcomes in patients referred with suspected PG at a tertiary ...
David Croitoru, Nesrine Brahimi, Haleh Zabihi, Cathryn Sibbald, Kyle Seigel, Delaram Shojaei, Eric McMullen, Afsaneh Alavi, Lily Archaempong, Aaron M. Drucker, Adam Weizman, Kenneth Croitoru, Robert Inman, Vincent Piguet   +13 more
wiley   +1 more source

Connecting the use of innovative treatments and glucocorticoids with the multidisciplinary evaluation through rule-based natural-language processing: a real-world study on patients with rheumatoid arthritis, psoriatic arthritis, and psoriasis. [PDF]

Front Med (Lausanne), 2023
Motta F, Morandini P, Maffia F, Vecellio M, Tonutti A, De Santis M, Costanzo A, Puggioni F, Savevski V, Selmi C.   +9 more
europepmc   +1 more source

Patient Characteristics, Disease Profile and Treatment Patterns in Mild and Moderate Psoriasis Patients: Results From Real‐World Clinical Practices in Five European Countries (PROSPECT Study)

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Categorisation of psoriasis (PsO) disease severity in patients varies, although body surface area (BSA) affected is commonly used (< 3% ‘mild’, 3%–10% ‘moderate’ and > 10% ‘severe’). While moderate‐severe PsO has been well‐studied, more limited information regarding mild‐to‐moderate PsO is available.
Emily Goddard, Aaron Keal, James Hetherington, Sophie Barlow, David Wu, Melany Worbes‐Cerezo, Alexander Litvintchouk   +6 more
wiley   +1 more source

Concurrent Psoriasis and Dermatomyositis: Retrospective Analysis and Literature Review

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis (PsO) and dermatomyositis (DM) are both autoimmune‐mediated, inflammatory conditions. The concurrence of PsO and DM is rare, and literature on their relationship remains limited. Additionally, cutaneous DM can be challenging to clinically diagnosis, often presenting with psoriasiform clinical features.
Emily R. Gordon, Karishma S. Shah, Sidharth Chand, Bonnie Lee, Janellen Smith, Michelle S. Min   +5 more
wiley   +1 more source